185 related articles for article (PubMed ID: 26088113)
1. Emerging Drugs and Indications for Cardio-Metabolic Disorders in People with Severe Mental Illness.
Kouidrat Y; Amad A; De Hert M
Curr Pharm Des; 2015; 21(23):3317-24. PubMed ID: 26088113
[TBL] [Abstract][Full Text] [Related]
2. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
[TBL] [Abstract][Full Text] [Related]
3. Metabolic Syndrome and Cardiovascular Risk in People Treated with Long-Acting Injectable Antipsychotics.
Sanchez-Martinez V; Romero-Rubio D; Abad-Perez MJ; Descalzo-Cabades MA; Alonso-Gutierrez S; Salazar-Fraile J; Montagud V; Facila L
Endocr Metab Immune Disord Drug Targets; 2018; 18(4):379-387. PubMed ID: 29165095
[TBL] [Abstract][Full Text] [Related]
4. Treatment of the metabolic disturbances caused by antipsychotic drugs: focus on potential drug interactions.
Baptista T; Kin NM; Beaulieu S
Clin Pharmacokinet; 2004; 43(1):1-15. PubMed ID: 14715048
[TBL] [Abstract][Full Text] [Related]
5. Off-Label Prescribing of Antipsychotics in Adults, Children and Elderly Individuals: A Systematic Review of Recent Prescription Trends.
Carton L; Cottencin O; Lapeyre-Mestre M; Geoffroy PA; Favre J; Simon N; Bordet R; Rolland B
Curr Pharm Des; 2015; 21(23):3280-97. PubMed ID: 26088115
[TBL] [Abstract][Full Text] [Related]
6. Editorial: Off-label Treatments for Mental Health: Inappropriate or Unavoidable? A Special Issue to Help Get Through the Maze.
Rolland B; Amad A
Curr Pharm Des; 2015; 21(23):3274-5. PubMed ID: 26238988
[No Abstract] [Full Text] [Related]
7. Cardio-metabolic risk in individuals prescribed long-acting injectable antipsychotic medication.
Morell R; Curtis J; Watkins A; Poole J; Fibbins H; Rossimel E; Gerrard M; White A; Teasdale S; Ward PB; Lappin J
Psychiatry Res; 2019 Nov; 281():112606. PubMed ID: 31629301
[TBL] [Abstract][Full Text] [Related]
8. Sense and Sensibility When Prescribing 'Off-Label' to Psychiatric Patients.
Baldwin DS; Tiwari N; Gordon R
Curr Pharm Des; 2015; 21(23):3276-9. PubMed ID: 26088118
[TBL] [Abstract][Full Text] [Related]
9. Metabolic issues and cardiovascular disease in patients with psychiatric disorders.
Casey DE
Am J Med; 2005 Apr; 118 Suppl 2():15S-22S. PubMed ID: 15903291
[TBL] [Abstract][Full Text] [Related]
10. Impact of co-morbid mental illness on the diagnosis and management of patients hospitalized for medical conditions in a general hospital.
Briskman I; Bar G; Boaz M; Shargorodsky M
Int J Psychiatry Med; 2012; 43(4):339-48. PubMed ID: 23094466
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the Appropriateness of Off-Label Antipsychotic Use for Mental Health Indications in a Veteran Population.
Painter JT; Owen R; Henderson KL; Bauer MS; Mittal D; Hudson TJ
Pharmacotherapy; 2017 Apr; 37(4):438-446. PubMed ID: 28164355
[TBL] [Abstract][Full Text] [Related]
12. Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome?
Katsiki N; Perez-Martinez P; Anagnostis P; Mikhailidis DP; Karagiannis A
Curr Vasc Pharmacol; 2018; 16(3):219-227. PubMed ID: 28669328
[TBL] [Abstract][Full Text] [Related]
13. Obesity in patients with severe mental illness: overview and management.
McElroy SL
J Clin Psychiatry; 2009; 70 Suppl 3():12-21. PubMed ID: 19570497
[TBL] [Abstract][Full Text] [Related]
14. New and emerging pharmacologic therapies for type 2 diabetes, dyslipidemia, and obesity.
Taylor JR; Dietrich E; Powell JG
Clin Ther; 2013 Jan; 35(1):A3-17. PubMed ID: 23328274
[TBL] [Abstract][Full Text] [Related]
15. Metabolic syndrome and mental illness.
Newcomer JW
Am J Manag Care; 2007 Nov; 13(7 Suppl):S170-7. PubMed ID: 18041878
[TBL] [Abstract][Full Text] [Related]
16. Rosemary (Rosmarinus officinalis) as a potential therapeutic plant in metabolic syndrome: a review.
Hassani FV; Shirani K; Hosseinzadeh H
Naunyn Schmiedebergs Arch Pharmacol; 2016 Sep; 389(9):931-49. PubMed ID: 27178264
[TBL] [Abstract][Full Text] [Related]
17. Drug combinations for dyslipidemia and obesity treatment in metabolic syndrome.
Florentin M; Elisaf MS; Mikhailidis DP; Liberopoulos EN
Curr Pharm Des; 2009; 15(29):3446-62. PubMed ID: 19860690
[TBL] [Abstract][Full Text] [Related]
18. Off-Label Trazodone Prescription: Evidence, Benefits and Risks.
Bossini L; Coluccia A; Casolaro I; Benbow J; Amodeo G; De Giorgi R; Fagiolini A
Curr Pharm Des; 2015; 21(23):3343-51. PubMed ID: 26088119
[TBL] [Abstract][Full Text] [Related]
19. Managing weight gain in patients with severe mental illness.
McIntyre RS
J Clin Psychiatry; 2009 Jul; 70(7):e23. PubMed ID: 19653969
[TBL] [Abstract][Full Text] [Related]
20. Metabolic syndrome in mental illness: evidence and way out.
Saddichha S
Int J Clin Pharmacol Ther; 2010 Jan; 48(1):84-6. PubMed ID: 20040344
[No Abstract] [Full Text] [Related]
[Next] [New Search]
